Serum perfluorinated compound concentration and attention deficit/hyperactivity disorder in children 5-18 years of age

Environmental Health Perspectives

Volumn 119, Issue 10, 2011, Pages 1466-1471

  Stein, Cheryl R ^a   Savitz, David A ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Adolescent; Attention deficit disorders; Child; Epidemiology; Fluorocarbons; Perfluorooctanoic acid

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; CARBAMAZEPINE; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DRINKING WATER; GUANFACINE; IMIPRAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NORTRIPTYLINE; PERFLUORO COMPOUND; PERFLUOROHEXANE SULFONATE; PERFLUORONONANOIC ACID; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD LEVEL; CHILD; CROSS-SECTIONAL STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SELF REPORT; WATER CONTAMINATION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FLUOROCARBONS; HUMANS; MALE; OCTANOIC ACIDS; SULFONIC ACIDS;

EID: 80053450446     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1003538     Document Type: Article

References (43)

1. Aguiar A, Eubig PA, Schantz SL. 2010. Attention deficit/hyperactivity disorder: a focused overview for children's environmental health researchers. Environ Health Perspect 118:1646-1653.
2. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC:American Psychiatric Association.
3. Banerjee TD, Middleton F, Faraone SV. 2007. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr 96:1269-1274.
4. Bartell SM, Calafat AM, Lyu C, Kato K, Ryan PB, Steenland K. 2010. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect 118:222-228.
5. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. 2006. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect 114:1904-1909.
6. Bussing R, Mason DM, Leon CE, Sinha K. 2003. Agreement between CASA parent reports and provider records of children's ADHD services. J Behav Health Serv Res 30:462-469.
7. Butenhoff JL, Kennedy GL Jr, Frame SR, O'Connor JC, York RG. 2004. The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology 196:95-116.
8. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. 2007a. Serum concentrations of 11 polyfluoroalkyl compounds in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES). Environ Sci Technol 41:2237-2242.
9. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. 2007b. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ Health Perspect 115:1596-1602.
10. CDC (Centers for Disease Control and Prevention). 2009. A SAS Program for the CDC Growth Charts. Available: http://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm [accessed 20 October 2010].
11. CDC (Centers for Disease Control and Prevention). 2010. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children-United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 59:1439-1443.
12. Daley CE, Onwuegbuzie AJ, Griffin H. 1998. Attention-deficit/hyperactivity disorder: relations between prevalence rate and school district size, diagnostic method, and referral process. Psychol Rep 83:593-594.
13. Desquilbet L, Mariotti F. 2010. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med; doi:10.1002/sim.3841 [Online 19 January 2010].
14. Emmett EA, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM. 2006. Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. J Occup Environ Med 48:759-770.
15. Eubig PA, Aguiar A, Schantz SL. 2010. Lead and PCBs as risk factors for attention deficit/hyperactivity disorder. Environ Health Perspect 118:1654-1667.
16. Fei C, McLaughlin JK, Lipworth L, Olsen J. 2008. Prenatal exposure to perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) and maternally reported developmental milestones in infancy. Environ Health Perspect 116:1391-1395.
17. Frisbee SJ, Brooks AP Jr, Maher A, Flensborg P, Arnold S, Fletcher T, et al. 2009. The C8 health project: design, methods, and participants. Environ Health Perspect 117:1873-1882.
18. Fuentes S, Colomina MT, Vicens P, Domingo JL. 2007. Influence of maternal restraint stress on the long-lasting effects induced by prenatal exposure to perfluorooctane sulfonate (PFOS) in mice. Toxicol Lett 171:162-170.
19. Fulton BD, Scheffler RM, Hinshaw SP, Levine P, Stone S, Brown TT, et al. 2009. National variation of ADHD diagnostic prevalence and medication use: health care providers and education policies. Psychiatr Serv 60:1075-1083.
20. Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM. 2010. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. Environ Health Perspect 118:1762-1767.
21. Houde M, Martin JW, Letcher RJ, Solomon KR, Muir DC. 2006. Biological monitoring of polyfluoroalkyl substances: a review. Environ Sci Technol 40:3463-3473.
22. Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima S, et al. 2004. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 112:1204-1207.
23. Kuklenyik Z, Reich JA, Tully JS, Needham LL, Calafat AM. 2004. Automated solid-phase extraction and measurement of perfluorinated organic acids and amides in human serum and milk. Environ Sci Technol 38:3698-3704.
24. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99:366-394.
25. Lau C, Butenhoff JL, Rogers JM. 2004. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 198:231-241.
26. Luebker DJ, Case MT, York RG, Moore JA, Hansen KJ, Butenhoff JL. 2005. Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology 215:126-148.
27. Midasch O, Drexler H, Hart N, Beckmann MW, Angerer J. 2007. Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. Int Arch Occup Environ Health 80:643-648.
28. Monroy R, Morrison K, Teo K, Atkinson S, Kubwabo C, Stewart B, et al. 2008. Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ Res 108:56-62.
29. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115:1298-1305.
30. Olsen GW, Butenhoff JL, Zobel LR. 2009. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol 27:212-230.
31. Pastor PN, Reuben CA. 2008. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 10:1-14.
32. Rothman KJ, Greenland S. 1998. Modern Epidemiology. 2nd ed. Philadelphia:Lippincott-Raven.
33. Schneider H, Eisenberg D. 2006. Who receives a diagnosis of attention-deficit/ hyperactivity disorder in the United States elementary school population? Pediatrics 117:e601-e609.
34. So MK, Yamashita N, Taniyasu S, Jiang Q, Giesy JP, Chen K, et al. 2006. Health risks in infants associated with exposure to perfluorinated compounds in human breast milk from Zhoushan, China. Environ Sci Technol 40:2924-2929.
35. Steenland K, Jin C, MacNeil J, Lally C, Ducatman A, Vieira V, et al. 2009. Predictors of PFOA levels in a community surrounding a chemical plant. Environ Health Perspect 117:1083-1088.
36. Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, et al. 2007. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 17:39-59.
37. Tao L, Kannan K, Wong CM, Arcaro KF, Butenhoff JL. 2008a. Perfluorinated compounds in human milk from Massachusetts, U.S.A. Environ Sci Technol 42:3096-3101.
38. Tao L, Ma J, Kunisue T, Libelo EL, Tanabe S, Kannan K. 2008b. Perfluorinated compounds in human breast milk from several Asian countries, and in infant formula and dairy milk from the United States. Environ Sci Technol 42:8597-8602.
39. U.S. EPA (U.S. Environmental Protection Agency). 2009a. Perfluorooctanoic Acid (PFOA) and Fluorinated Telomers. Available: http://www.epa.gov/oppt/pfoa/index.html [accessed 21 January 2009].
40. U.S. EPA (U.S. Environmental Protection Agency). 2009b. Perfluorooctanoic Acid (PFOA) and Fluorinated Telomers Basic Information. Available: http://www.epa.gov/oppt/pfoa/pubs/pfoainfo.html [accessed 21 January 2009].
41. Vestergren R, Cousins IT. 2009. Tracking the pathways of human exposure to perfluorocarboxylates. Environ Sci Technol 43:5565-5575.
42. Volkel W, Genzel-Boroviczeny O, Demmelmair H, Gebauer C, Koletzko B, Twardella D, et al. 2008. Perfluorooctane sulphonate (PFOS) and perfluorooctanoic acid (PFOA) in human breast milk: results of a pilot study. Int J Hyg Environ Health 211:440-446.
43. White SS, Fenton SE, Hines EP. 2011. Endocrine disrupting properties of perfluorooctanoic acid. J Steroid Biochem Mol Biol; doi:10.1016/j.jsbmb.2011.03.011 [Online 11 March 2011].